ERBB2 and breast cancer: Approximately 15%–30% of IHC 2+ cases are HER2-amplified (29), while the remaining IHC 2+ and IHC 1+ HER2 non-amplified tumors were recently designated as a relatively common “HER2-low” category, accounting for approximately 40%–55% of BC (30–32).